iTeos Therapeutics acquired by Concentra Biosciences for $10.047/sh plus CVR

iTeos Therapeutics, Inc.

Tender offer closed with 72.17% of shares tendered; all conditions satisfied; merger effective Aug 29, 2025.
Shareholders receive $10.047 cash per share plus one non-transferable CVR per share.
CVR entitles holders to 80% of net proceeds from future disposition of specific product candidates (EOS-984, EOS-215, PTPN1/2 program) within 6-month disposition period.
Board resigned; new directors/officers from Concentra (Kevin Tang CEO, Michael Hearne CFO, etc.).
Company requests delisting from Nasdaq and intends to deregister with SEC.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.